Diagnostics News and Research

RSS

New Technology Enables Whole-Body Analysis of Gene Expression

Understanding gene expression within the body has been a boon for 21st century biology and therapeutics, but most discoveries that use these technologies only focus on one organ or one small area of tissue.

30 Mar 2026

New Mechanism Links Mitochondria Dysfunction to T Cell Exhaustion

The immune system's killer T cells do a commendable job of detecting and destroying cancer cells. But the harsh environment at the heart of tumors often saps them of their vitality, pushing them into a state of permanent lassitude called "terminal exhaustion."

23 Mar 2026

Advanced Genome Sequencing Reveals Hidden Genetic Variants Linked to Autism

Researchers at the University of California San Diego have identified new genetic variants associated with autism spectrum disorder (ASD) by using long-read whole genome sequencing (LR-WGS), an emerging approach that reads large sections of the genome at once, making it easier for scientists to find new genetic variants and understand how genetic variants affect the function of a gene.

10 Mar 2026

Study Warns AI Often Predicts Gene Mutations by Looking at Unrelated Traits

New research warns that popular deep learning systems trained for cancer pathology may be relying on hidden shortcuts rather than genuine biological signals.

3 Mar 2026

High-Speed Algorithm Transforms Telomere to Telomere Genome Sequencing

Haoyu Cheng, PhD, assistant professor of biomedical informatics and data science at Yale School of Medicine, has developed a new algorithm capable of building complete human genomes using standard laboratory technology.

27 Feb 2026

Danaher to Acquire Masimo Corporation

Danaher Corporation, a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings.

From Danaher Life Sciences 24 Feb 2026

Artificial Intelligence Enables Stable Intrabody Design in Cells

A new artificial intelligence-driven pipeline developed in a collaborative research combines protein structure prediction, sequence design, and live-cell screening together to enable rapid conversion of antibody sequences into functional intracellular antibodies (intrabodies) that are stable within living cells.

16 Feb 2026

Powerful New Enzyme Efficiently Synthesizes RNA

From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine.

10 Feb 2026

Aged Neutrophils With CCL3 Drive Tumor Growth Across Cancers

Renowned as first responders to threatening infections, neutrophils also happen to feature prominently in the microenvironment of tumors, where they and other immune cells play opposing and frequently mutable roles in promoting-or resisting-cancer progression.

6 Feb 2026

Lightweight AI Model Reveals Rules Governing Gene Regulation

Gene regulation is far more predictable than previously believed, scientists conclude after developing deep learning model PARM.

5 Feb 2026

New Boron Compounds Enable Easier Drug Modification Without Breakdown

A major step towards simpler drug development has been taken at the University of Gothenburg. In a new study, researchers have developed stable boron-fluorine compounds that make it possible to increase the effect or reduce side effects without breaking down the medicine.

4 Feb 2026

Sugar Molecules Point to a New Weapon Against Drug-Resistant Bacteria

Australian researchers have developed a powerful new way to target deadly, drug-resistant bacteria by designing antibodies that recognize a sugar found only on bacterial cells – an advance that could underpin a new generation of immunotherapies for multidrug resistant hospital-acquired infections.

4 Feb 2026

Blood protein test helps spot hidden cancers in patients with vague symptoms

Plasma protein profiling offers a promising tool for cancer risk stratification in patients with non-specific symptoms, potentially reducing diagnostic delays.

28 Jan 2026

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State University Wexner Medical Center (OSU-WMC), was initiated to explore whether donor-derived cell-free DNA (dd-cfDNA) surveillance, and specifically Prospera-guided monitoring, could reduce the number of invasive biopsies for patients following lung transplantation.

From Natera 27 Jan 2026

Single Enzyme Enables Low-Cost Synthesis of All RNA Nucleotides

A single enzyme that can generate all four nucleotide triphosphates, the building blocks of ribonucleic acid (RNA), was identified by researchers at the Institute of Science Tokyo.

24 Jan 2026

Hidden Sperm RNA Remodeling With Age May Impact Next Generation

Increasing paternal age has been linked to elevated health risks for the next generation, including higher risks of obesity and stillbirth. But what drives this increased risk remains unknown.

21 Jan 2026

First Fully Synthetic Bacteriophage Engineering System for Antibiotic-Resistant Bacterium

Bacteriophages have been used therapeutically to treat infectious bacterial diseases for over a century.

21 Jan 2026

Study Overturns Understanding About How T Cells Recognize Lipid Antigens

A new discovery about how cells communicate with each other in the body's immune system has revealed deeper insights for an international team of scientists into fundamental immune system function.

16 Jan 2026

Blocking Retinoic Acid Pathway Improves Dendritic Cell Anti-Tumor Function

Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by which a metabolic derivative of vitamin A-all-trans retinoic acid-compromises both the body's normal anti-cancer immune response and, in a different context, the efficacy of a promising type of cancer vaccine.

6 Jan 2026